AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16413699 — intervention group
Group type: COMPARATOR
Intervention: Patients with major deviations in treatment schedule
Number of subjects: 210
Study 16413699 — intervention group
Group type: COMPARATOR
Intervention: Patients without major deviations in treatment schedule
Number of subjects: 210
Study 16608381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propionyl L‐carnitine 600 mg 3 times weekly for 12 months
Number of subjects: 64
Study 16608381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 14597928 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (TT)
Number of subjects: 302
Study 10511934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling PRK
Number of subjects: 38
Study 10511934 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 38
Study 7734254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric amethocaine 8 mg
Number of subjects: 90
Study 7734254 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant group
Number of subjects: 90
Study 7734254 — intervention group
Group type: COMPARATOR
Intervention: First trimester group
Number of subjects: 90
Study 2271747 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg SR tablets after a high fat breakfast
Number of subjects: 28
Study 2271747 — intervention group
Group type: COMPARATOR
Intervention: 15 mg SR tablets in fasted state
Number of subjects: 28
Study 2271747 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg SR tablets 1 h before, 0.5 h after, 2 h after a high fat meal
Number of subjects: 28
Study 399768 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional assessments in hospital before discharge
Number of subjects: 0
Study 399768 — intervention group
Group type: COMPARATOR
Intervention: Functional assessments at home shortly after discharge
Number of subjects: 0
Study 31182442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription support-tool
Number of subjects: 230
Study 31182442 — intervention group
Group type: COMPARATOR
Intervention: No prescription support-tool (Control)
Number of subjects: 230
Study 27764726 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 71
Study 27764726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 71
Study 27764726 — intervention group
Group type: COMPARATOR
Intervention: Both RE and AE
Number of subjects: 71
Study 25879721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 495
Study 25879721 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy (PDT)
Number of subjects: 495
Study 25879721 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 495
Study 23599316 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV (tetravalent rotavirus vaccine)
Number of subjects: 998
Study 23599316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 998
Study 22052272 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% mulberry extract oil
Number of subjects: 50
Study 22052272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19660042 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous smoking
Number of subjects: 78
Study 19660042 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence with transdermal nicotine patch
Number of subjects: 78
Study 19660042 — intervention group
Group type: COMPARATOR
Intervention: Abstinence with placebo
Number of subjects: 78
Study 19660042 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 78
Study 17228060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 164
Study 17228060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training (BT)
Number of subjects: 164
Study 14756910 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 12
Study 14756910 — intervention group
Group type: COMPARATOR
Intervention: Cream (CREAM)
Number of subjects: 12
Study 18610663 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified spirometry technique
Number of subjects: 72
Study 18610663 — intervention group
Group type: COMPARATOR
Intervention: Standard FVC maneuver
Number of subjects: 72
Study 9205940 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 96
Study 9205940 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 96
Study 8392288 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 34
Study 8392288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3795326 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with mebendazole (1800 mg day-1 for 18 weeks)
Number of subjects: 10
Study 3795326 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted therapy with mebendazole (1800 mg day-1 for interrupted 6-week courses for a minimum of three courses, with intervals of 19-22 weeks)
Number of subjects: 10
Study 29648532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) tablet of repaglinide/metformin (2/500 mg)
Number of subjects: 50
Study 29648532 — intervention group
Group type: COMPARATOR
Intervention: Equivalent doses of individual (EDI) tablets of repaglinide (2 mg) and metformin (500 mg)
Number of subjects: 50
Study 31833938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 31833938 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30620666 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body higher-repetition RT (20-25 repetitions/set to failure at ∼30%-50% 1RM)
Number of subjects: 40
Study 30620666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-repetition RT (8-12 repetitions/set to failure at ∼75%-90% 1RM)
Number of subjects: 40
Study 30620666 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 40
Study 28635236 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoaiping combined with S‐1 and cisplatin
Number of subjects: 124
Study 28635236 — intervention group
Group type: COMPARATOR
Intervention: S‐1 and cisplatin
Number of subjects: 124
Study 26431653 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese drug iontophoresis
Number of subjects: 296
Study 26431653 — intervention group
Group type: COMPARATOR
Intervention: Medium frequency electrotherapy
Number of subjects: 296
Study 23221572 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (30% of energy from protein)
Number of subjects: 79
Study 23221572 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (15% of energy from protein)
Number of subjects: 79
Study 23221572 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (5% of energy from protein)
Number of subjects: 79
Study 21477901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol fortified orange juice (1g/240 ml juice twice a day)
Number of subjects: 72
Study 21477901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol fortified OJBev (1g/240 ml beverage twice a day)
Number of subjects: 72
Study 21477901 — intervention group
Group type: COMPARATOR
Intervention: Placebo OJ
Number of subjects: 72
Study 21477901 — intervention group
Group type: COMPARATOR
Intervention: Placebo OJBev
Number of subjects: 72
Study 19507292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment
Number of subjects: 10720
Study 19507292 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe cognitive impairment
Number of subjects: 10720
Study 19507292 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium social engagement
Number of subjects: 10720
Study 19507292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social engagement
Number of subjects: 10720
Study 19507292 — intervention group
Group type: COMPARATOR
Intervention: Higher level of social engagement
Number of subjects: 10720
Study 16779731 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 724
Study 16779731 — intervention group
Group type: COMPARATOR
Intervention: No enfuvirtide
Number of subjects: 724
Study 16779731 — intervention group
Group type: EXPERIMENTAL
Intervention: R5 strains
Number of subjects: 724
Study 16779731 — intervention group
Group type: EXPERIMENTAL
Intervention: D/M strains
Number of subjects: 724
Study 16779731 — intervention group
Group type: EXPERIMENTAL
Intervention: X4 strains
Number of subjects: 724
Study 15614460 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg ivermectin (110 microg/kg) administered as a single dose, repeated 2 weeks later
Number of subjects: 409
Study 15614460 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/kg ivermectin administered as a single dose, repeated 2 weeks later
Number of subjects: 409
Study 12032393 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 8000 anti-FXa units LMWH Certoparin
Number of subjects: 18
Study 12032393 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 8000 anti-FXa units LMWH Certoparin
Number of subjects: 18
Study 9640523 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (informed of cholesterol results after screening)
Number of subjects: 391
Study 9640523 — intervention group
Group type: COMPARATOR
Intervention: Control group (informed of cholesterol results before screening)
Number of subjects: 391
Study 9640523 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with abnormal cholesterol results
Number of subjects: 391
Study 8033876 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom-Foley catheter method (CFCM) with oxytocin
Number of subjects: 45
Study 8033876 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion alone
Number of subjects: 45
Study 2599730 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training program with running a marathon, divided into three phases with training volumes of 45, 70, and 110 km/week.
Number of subjects: 114
Study 2599730 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training program with running a marathon.
Number of subjects: 114
Study 785948 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol administered for 16 weeks
Number of subjects: 10
Study 30611454 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (36 sessions over 12 weeks)
Number of subjects: 500
Study 30611454 — intervention group
Group type: COMPARATOR
Intervention: PFMT plus solifenacin (5 mg/d over 36 weeks)
Number of subjects: 500
Study 27282116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (2000μg)
Number of subjects: 35
Study 27282116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27282116 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D responsiveness classification
Number of subjects: 35
Study 25494974 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute sprint interval exercise (SIE)
Number of subjects: 8
Study 25494974 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 8
Study 22616628 — intervention group
Group type: COMPARATOR
Intervention: GSK679586 (0.005, 0.05, 0.5, 2.5, 10 mg kg(‐1))
Number of subjects: 0
Study 22616628 — intervention group
Group type: COMPARATOR
Intervention: GSK679586 (2.5, 10, 20 mg kg(‐1))
Number of subjects: 0
Study 22616628 — intervention group
Group type: COMPARATOR
Intervention: GSK679586
Number of subjects: 0
Study 21818506 — intervention group
Group type: EXPERIMENTAL
Intervention: SRD174 cream
Number of subjects: 62
Study 21818506 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 62
Study 19514618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 10917
Study 19514618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10917
Study 16430549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 98
Study 16430549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 98
Study 16430549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 98
Study 15262456 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 1213
Study 15262456 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 1213
Study 11012239 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAN-C Test for Auditory Processing Disorders in Children-Revised
Number of subjects: 650
Study 8936586 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiestrogen regimen (tamoxifen or toremifene)
Number of subjects: 38
Study 1631876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood temperature of 20 degrees C
Number of subjects: 20
Study 1631876 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative blood temperature of 28 degrees C
Number of subjects: 20
Study 6431795 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual isosorbide dinitrate (ISDN)
Number of subjects: 10
Study 6431795 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerin (NTG)
Number of subjects: 10
Study 31968059 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 640
Study 31968059 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 640
Study 31177581 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius K12 plus nystatin
Number of subjects: 56
Study 31177581 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nystatin
Number of subjects: 56
Study 28368738 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 7359
Study 28368738 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 7359
Study 26799892 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention program including one Skype session and six weeks of daily directive text messages guiding app use.
Number of subjects: 0
Study 26799892 — intervention group
Group type: COMPARATOR
Intervention: Control condition (details not specified).
Number of subjects: 0
Study 23181710 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.05% + Fluoride 0.05%
Number of subjects: 30
Study 23181710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22077909 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab plus unfractionated heparin
Number of subjects: 1721
Study 22077909 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 1721
Study 18754096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg every 24 h
Number of subjects: 26
Study 18754096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg every 12 h (q12h)
Number of subjects: 26
Study 18754096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 80 mg q12h
Number of subjects: 26
Study 17005051 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 75
Study 17005051 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 14684622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (100 physicians) received individual visits up to three times over a 2-year period with educational material and personal laboratory test utilization data.
Number of subjects: 200
Study 14684622 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 physicians) did not receive the intervention.
Number of subjects: 200
Study 10707752 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose captopril (50 mg b.i.d.)
Number of subjects: 298
Study 10707752 — intervention group
Group type: COMPARATOR
Intervention: Low dose captopril (25 mg b.i.d.)
Number of subjects: 298
Study 9226142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric bootstrap method
Number of subjects: 0
Study 9226142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fieller theorem method
Number of subjects: 0
Study 9226142 — intervention group
Group type: EXPERIMENTAL
Intervention: Taylor series method
Number of subjects: 0
Study 9226142 — intervention group
Group type: EXPERIMENTAL
Intervention: Box method
Number of subjects: 0
Study 1357516 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin (2400 mg daily for 3 weeks)
Number of subjects: 23
Study 1357516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3907494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxacillin plus rifampin (12 g/day, intravenously; rifampin 1,200 mg/day, orally)
Number of subjects: 101
Study 3907494 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin plus placebo (12 g/day, intravenously)
Number of subjects: 101
Study 2439344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimen (methotrexate 30 mg/m2, bleomycin 15 mg, hydroxyurea 1000 mg/m2, cisplatin 60 mg/m2)
Number of subjects: 62
Study 2439344 — intervention group
Group type: COMPARATOR
Intervention: 3-drug combination (methotrexate 30 mg/m2, bleomycin 15 mg, hydroxyurea 1000 mg/m2)
Number of subjects: 62
Study 2439344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimen
Number of subjects: 62
Study 31411903 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Consultation (BC)
Number of subjects: 127
Study 31411903 — intervention group
Group type: COMPARATOR
Intervention: No Behavioral Consultation (NoBC)
Number of subjects: 127
Study 29389467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-competition massage
Number of subjects: 17
Study 29389467 — intervention group
Group type: COMPARATOR
Intervention: Dynamic warm-up
Number of subjects: 17
Study 29389467 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of massage and warm-up
Number of subjects: 17
Study 29389467 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound
Number of subjects: 17
Study 27136409 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Parent Empowerment intervention
Number of subjects: 46
Study 27136409 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 46
Study 25900644 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective symptoms
Number of subjects: 362
Study 25900644 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective symptoms
Number of subjects: 362
Study 23070803 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day)
Number of subjects: 450
Study 21112549 — intervention group
Group type: EXPERIMENTAL
Intervention: Radachlorin® solution for intravenous infusions 0.35% 10mL at doses of 0.5‐0.6 and 1.0‐1.2mg/kg
Number of subjects: 0
Study 21112549 — intervention group
Group type: EXPERIMENTAL
Intervention: Radachlorin® gel for topical application 0.1% 25g at a dose of 0.1g/cm(2)
Number of subjects: 0
Study 21112549 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug administration at a dose of 1.0‐1.2mg/kg and irradiation at 3h with 662±3nm light at a dose of 300J/cm(2) (solution)
Number of subjects: 0
Study 21112549 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 PDT sessions at an interval of 1 week with 3h gel exposure, followed by 400J/cm(2) light exposure (gel)
Number of subjects: 0
Study 18257397 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab
Number of subjects: 89
Study 18257397 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab
Number of subjects: 89
Study 18257397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 16801295 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-organizing approach to restrict retail sale of tobacco to youth for 32 months
Number of subjects: 14
Study 16801295 — intervention group
Group type: COMPARATOR
Intervention: Control communities (no specific intervention)
Number of subjects: 14
Study 14606076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy with splenectomy
Number of subjects: 26
Study 14606076 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy without splenectomy
Number of subjects: 26
Study 11003362 — intervention group
Group type: EXPERIMENTAL
Intervention: EOS-guided steroid dose adjustment (RG)
Number of subjects: 80
Study 11003362 — intervention group
Group type: COMPARATOR
Intervention: No EOS monitoring (NG)
Number of subjects: 80
Study 8872667 — intervention group
Group type: EXPERIMENTAL
Intervention: Air rich in CO2 (CO2 exposure)
Number of subjects: 4
Study 8872667 — intervention group
Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 4
Study 1523144 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg buscopan
Number of subjects: 41
Study 1523144 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 41
Study 1523144 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg papaverine
Number of subjects: 41
Study 1523144 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of 0.9% NaCl solution
Number of subjects: 41
Study 6478752 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 60% oxygen
Number of subjects: 5
Study 6478752 — intervention group
Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 5
Study 30666153 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-C1 (0.035 mg/kg bodyweight, daily intramuscular injection for 32 days)
Number of subjects: 31
Study 30666153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal-looking, for 32 days)
Number of subjects: 31
Study 30666153 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-C1 (after crossover from placebo)
Number of subjects: 31
Study 30666153 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-C1
Number of subjects: 31
Study 30666153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29947688 — intervention group
Group type: EXPERIMENTAL
Intervention: Single port laparoscopic cholecystectomy
Number of subjects: 57
Study 29947688 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 57
Study 27634487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g kg-1)
Number of subjects: 10
Study 27634487 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (PLA)
Number of subjects: 10
Study 24828266 — intervention group
Group type: EXPERIMENTAL
Intervention: Minitab sprinkles (40 mg/10 mg)
Number of subjects: 77